

Pedro Aguiar JÃºnior

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8162345/publications.pdf>

Version: 2024-02-01

50
papers

634
citations

933447

10
h-index

580821

25
g-index

51
all docs

51
docs citations

51
times ranked

1509
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. <i>Immunotherapy</i> , 2017, 9, 499-506.	2.0	162
2	The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. <i>Immunotherapy</i> , 2016, 8, 479-488.	2.0	136
3	The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. <i>Annals of Oncology</i> , 2017, 28, 2256-2263.	1.2	72
4	Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer – A systematic review and network meta-analysis of 3024 participants. <i>Lung Cancer</i> , 2018, 115, 84-88.	2.0	39
5	A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. <i>Immunotherapy</i> , 2016, 8, 1011-1019.	2.0	34
6	Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. <i>ESMO Open</i> , 2017, 2, e000200.	4.5	31
7	Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 516-523.	3.9	25
8	Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer. <i>Einstein (Sao Paulo, Brazil)</i> , 2019, 17, eGS4414.	0.7	15
9	HUMAN DNA QUANTIFICATION IN THE STOOLS OF PATIENTS WITH COLORECTAL CANCER. <i>Arquivos De Gastroenterologia</i> , 2015, 52, 293-298.	0.8	11
10	Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer. <i>Einstein (Sao Paulo, Brazil)</i> , 2017, 15, 349-354.	0.7	11
11	MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer. <i>Immunotherapy</i> , 2015, 7, 1133-1134.	2.0	9
12	Genetic Polymorphisms of Vitamin D Metabolism Genes and Serum Level of Vitamin D in Colorectal Cancer. <i>International Journal of Biological Markers</i> , 2017, 32, 441-446.	1.8	9
13	EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2016, 11, 393-400.	1.6	8
14	A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors. <i>Drugs in Context</i> , 2018, 7, 1-6.	2.2	8
15	Disparities in cancer epidemiology and care delivery among Brazilian indigenous populations. <i>Einstein (Sao Paulo, Brazil)</i> , 2016, 14, 330-337.	0.7	7
16	HER2 EXPRESSION AS A PROGNOSTIC FACTOR IN METASTATIC GASTRIC CANCER. <i>Arquivos De Gastroenterologia</i> , 2016, 53, 62-67.	0.8	7
17	O.03: Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression. <i>Journal of Thoracic Oncology</i> , 2016, 11, S169-S170.	1.1	7
18	Definitive chemoradiotherapy for squamous head and neck cancer: cisplatin versus carboplatin? A meta-analysis. <i>Future Oncology</i> , 2016, 12, 2755-2764.	2.4	7

#	ARTICLE	IF	CITATIONS
19	Costâ€effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression. Lung Cancer Management, 2016, 5, 119-122.	1.5	5
20	Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding. Journal of Thoracic Oncology, 2020, 15, 1170-1176.	1.1	5
21	P2.03-006 How Many Years of Life Have We Lost in Brazil Due to the Lack of Access to Anti-EGFR TKIs in the National Public Health System?. Journal of Thoracic Oncology, 2017, 12, S2129.	1.1	4
22	Current advances in targeted therapies for metastatic gastric cancer: improving patient care. Future Oncology, 2016, 12, 839-854.	2.4	3
23	Patient-centered outcomes in non-small-cell lung cancer: a real-world perspective. Future Oncology, 2021, 17, 1721-1733.	2.4	3
24	Treating operable patients with gastric cancer: Macdonald's protocol versus adjuvant chemotherapy. Future Oncology, 2015, 11, 2247-2249.	2.4	2
25	Brazilian data of renal cell carcinoma in a public university hospital. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 29-36.	1.5	2
26	3122 The role of PD-L1 expression as a predictive biomarker in advanced non-small cell lung cancer: A network meta-analysis. European Journal of Cancer, 2015, 51, S644.	2.8	1
27	P2.45: An Estimate of the Economic Impact of Treatment of NSCLC With Immunotherapy Relative to PD-L1 Expression in Brazil. Journal of Thoracic Oncology, 2016, 11, S246.	1.1	1
28	OA17.01 Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US. Journal of Thoracic Oncology, 2017, 12, S308.	1.1	1
29	MA14.11 An Estimate of the Economic Impact of Immunotherapy Relative to PD-L1 Expression in Brazil - An Update with Brazilian Costs. Journal of Thoracic Oncology, 2017, 12, S427.	1.1	1
30	P2.07-055 Indirect Comparison between Immune-Checkpoint Inhibitors for 2nd Line Non-Small Cell Lung Cancer â€ a Network Meta-Analysis. Journal of Thoracic Oncology, 2017, 12, S2150.	1.1	1
31	P1.11-001 Economic Impact of Immune Checkpoint Inhibitor Therapy in Brazil and Strategies to Improve Access. Journal of Thoracic Oncology, 2017, 12, S2026.	1.1	1
32	P2.07-054 Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S2149-S2150.	1.1	1
33	Treatment of Metastatic Renal Cell Carcinoma: Latest Evidence and Ongoing Challenges. Clinical Medicine Insights Urology, 2018, 11, 117956111876575.	0.4	1
34	Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.. Journal of Clinical Oncology, 2016, 34, 9033-9033.	1.6	1
35	Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study. Sao Paulo Medical Journal, 2019, 137, 505-511.	0.9	1
36	Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer. Einstein (Sao Paulo, Brazil), 2022, 20, eGS6655.	0.7	1

#	ARTICLE	IF	CITATIONS
37	2826 Definitive chemoradiotherapy for loco-regionally advanced squamous cell head and neck cancer: Is cisplatin more effective than carboplatin? - a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, S566-S567.	2.8	0
38	1027 Disparities in cancer epidemiology and care delivery among Brazilian indigenous populations. <i>European Journal of Cancer</i> , 2015, 51, S154.	2.8	0
39	3080 Polled analysis of nivolumab for the treatment of advanced non-small cell lung cancer and the role of PD-L1 as a biomarker. <i>European Journal of Cancer</i> , 2015, 51, S624.	2.8	0
40	P2.44: An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a BIOMARKER. <i>Journal of Thoracic Oncology</i> , 2016, 11, S245.	1.1	0
41	PD1.02 (also presented as P2.47): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2016, 11, S171-S172.	1.1	0
42	Cost effectiveness and estimate of economical impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression. <i>Annals of Oncology</i> , 2016, 27, vi423.	1.2	0
43	P3.02b-081 Comparative Outcome Assessment of EGFR TKIs for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1239-S1240.	1.1	0
44	OA23.01 Anti-EGFR Monoclonal Antibodies plus Chemotherapy in the First-Line Treatment of Advanced NSCLC: A Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2017, 12, S333-S334.	1.1	0
45	P3.03-019 Activity of PARP Inhibitor in NSCLC with Germline and Somatic Mutation and in Silico Chemotherapy Lethality. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2280.	1.1	0
46	Individualized Chemotherapy for Metastatic Gastric Cancer: Retrospective Data from a University Hospital in Brazil. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 5289-5296.	1.2	0
47	Atezolizumab for previous treated advanced non-small-cell lung cancer: should it be worthy for the clinical practice?. <i>AME Medical Journal</i> , 0, 2, 34-34.	0.4	0
48	Temporary Dysarthria Induced by Irinotecan-Case Report of This Rare Adverse Event. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 5, .	0.0	0
49	Predictive genetic biomarkers in immune checkpoint inhibitors for non-small-cell lung cancer.. <i>Immunotherapy</i> , 2022, , .	2.0	0
50	Laboratory variables as predictors of progression in gastroenteropancreatic neuroendocrine tumors in different lines of antineoplastic treatments. <i>Einstein (Sao Paulo, Brazil)</i> , 2022, 20, .	0.7	0